Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2019

View Archived Issues

Novel mouse models of chronic sustained hypoxia and chronic intermittent hypoxia

OP-1250 shrinks ER-positive breast tumors in xenograft models

Vaccitech Oncology collaborates with Cancer Research UK on phase I/IIa study of VTP-600 vaccine

Zentalis begins phase I/II trial of DDR drug candidate ZN-c3

Genistein analogue AXP-107-11 acts as chemoenhancer in pancreatic ductal adenocarcinoma

Lack of clinical effect with AVL-3288 in phase Ib trial in schizophrenia patients

Freeline Therapeutics describes novel next-generation AAV-hFVIII vector candidate

Microbiome-based therapies may be useful against ALDs

Ryaltris receives marketing approval in Australia

'Aggrephagy' is viral immune evasion mechanism

Jiangsu Vcare Pharmatech describes new EGFR inhibitors

New cannabinoid CB1/2 receptor ligands discovered at AL&AM Pharmachem

Shionogi presents new histone deacetylase inhibitors

Merck & Co. patents HIV integrase inhibitors

New protein cereblon ligands identified at C4 Therapeutics

FDA approves Dayvigo for insomnia

Orkedia approved in Japan for hypercalcemia in parathyroid carcinoma or primary hyperparathyroidism

FDA approves Enhertu for unresectable or metastatic HER2-positive breast cancer

Quantum Genomics begins phase III study of firibastat in hypertension

New INDUCE-3 trial studies GSK-3359609 and pembrolizumab for PD-L1-positive HNSCC

FDA issues complete response letter for long-acting cabotegravir/rilpivirine regimen for HIV

InxMed gains clearance in China for phase I trial of IN-10018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...